Northwestern Mutual Investment Management Company LLC decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 83.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,256 shares of the medical equipment provider’s stock after selling 47,202 shares during the quarter. Northwestern Mutual Investment Management Company LLC’s holdings in Hologic were worth $320,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HOLX. Miles Capital Inc. acquired a new position in Hologic in the 1st quarter worth about $206,000. Beck Mack & Oliver LLC acquired a new position in Hologic in the 2nd quarter worth about $209,000. Stratos Wealth Partners LTD. acquired a new position in Hologic in the 1st quarter worth about $210,000. Notis McConarty Edward acquired a new position in Hologic in the 2nd quarter worth about $213,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in Hologic in the 2nd quarter worth about $213,000. 96.38% of the stock is owned by institutional investors.
In related news, VP Karleen Marie Oberton sold 4,704 shares of Hologic stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Elaine Ullian sold 8,849 shares of Hologic stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $45.28, for a total value of $400,682.72. Following the transaction, the director now owns 23,810 shares of the company’s stock, valued at $1,078,116.80. The disclosure for this sale can be found here. Insiders have sold a total of 27,594 shares of company stock valued at $1,168,871 over the last 90 days. Insiders own 0.79% of the company’s stock.
Several equities research analysts have commented on the company. Royal Bank Of Canada cut their price objective on Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a research note on Thursday, August 3rd. BidaskClub lowered Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research upgraded Hologic from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Barclays PLC cut their price objective on Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a research note on Thursday, August 3rd. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $48.64.
Shares of Hologic, Inc. (NASDAQ:HOLX) opened at 37.72 on Monday. The stock has a 50 day moving average price of $38.90 and a 200-day moving average price of $42.58. The stock has a market capitalization of $10.58 billion, a price-to-earnings ratio of 14.05 and a beta of 0.92. Hologic, Inc. has a 52-week low of $35.15 and a 52-week high of $46.80.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The firm had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. During the same period in the previous year, the firm posted $0.51 EPS. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. On average, equities research analysts predict that Hologic, Inc. will post $2.01 EPS for the current fiscal year.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.